CIK细胞回输联合沙培林膀胱灌注预防表浅膀胱癌术后复发

目的探讨CIK细胞回输联合沙培林膀胱灌注预防表浅膀胱癌术后复发的疗效。方法对67例多发性浅表性膀胱癌患者术后进行免疫治疗，其中CIK细胞回输联合沙培林膀胱灌注36例，单用沙培林膀胱灌注31例。随访12—26个月，监测两组患者治疗后是否复发以及复发的时间。结果联合治疗组无肿瘤复发率97．22％（35／36），肿瘤复发率2．78％（1／36），复发1例为PT1G2-3，复发时间为术后第24个月。单用沙培林组无肿瘤复发率80．65％（25／31），肿瘤复发率19．35％（6／31），两组病例在肿瘤复发率的比较差异有统计学意义（P〈0．05）。结论CIK细胞回输联合沙培林膀胱灌注可有效预防浅表性膀胱癌术后复发，远期效果有待进一步观察。

Cytokine induced killer(CIK) cells infusion combination with intravesical instillation of OK-432 in the prophylaxis of local recurrence after resection of bladder cancer

Objective To study the efficacy and safety of cytokine induced killer cells infusion combination with intravesical instillation of OK-432 in the prophylaxis of local recurrence after resection of bladder cancer. Methods 67 patients with bladder cancer after TURBt or partial cystectomy. 36 cases received CIK infusion combination with intravesical instillation of OK-432 （ Group A ） and 31 cases received single intravesical instillation of OK-432 （ Group B ）. All these patients were followed up for 12 to 26 months. Results The recurrence rate in group A was 2.78% （1/36）. Only 1 patient （ PT1G2-3 ） was detected recurrence in the 24th month after operation. No systemic side effect was observed in this group. 6 cases in group B were detected bladder tumor recurrence （ 2 of PTaG1-2 , 3 of PT1G2-3 and 1 of PT2G3 ） in the 21st , 17th, 12 nd, 11st ,9th and 4th month after the operation respectively. The recurrent rate of group A is significantly lower than that of group B （P〈0.05）. Conclusion cytokine induced killer cells infusion combination with intravesical instillation of OK-432 is an effective and safe therapy in prevent local recurrence of bladder cancer post-operation and need further study.